Myeloma cells and bone marrow osteoblast interactions: Role in the development of osteolytic lesions in multiple myeloma

References

• Kyle R A, Rajkumar S V. Multiple myeloma. N Engl J Med 2004; 351: 1860–1873
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004; 32: 685–691
   PubMed Web of Science ®Google Scholar
• Giuliani N, Rizzoli V, GD Roodman. Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992–3996
   PubMed Web of Science ®Google Scholar
• Vejlgaard T, Abildgaard N, Jans H, Nielsen J L, Heickendorff L. Abnormal bone turnover in monoclonal gamyelomaopathy of undetermined significance: analyses of type I collagen telopeptide, osteocalcin, bone-specific alkaline phosphatase and propeptides of type I and type III procollagens. Eur J Haematol 1997; 58: 104–108
   PubMed Web of Science ®Google Scholar
• Hjorth-Hansen H, Seifert M F, Börset M, Aarset H, Ostlie A, Sundan A, et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined imyelomaunodeficiency mice. J Bone Miner Res 1999; 14: 256–263
   PubMed Web of Science ®Google Scholar
• Evans C E, Ward C, Rathour L, Galasko C B. Myeloma affects both the growth and function of human osteoblast-like cells. Clin Exp Metastasis 1992; 10: 33–38
   PubMed Web of Science ®Google Scholar
• Silvestris F, Cafforio P, Tucci M, Grinello D, Damyelomaacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 2003; 122: 39–52
   PubMed Web of Science ®Google Scholar
• Tinhofer I, Biedermann R, Krismer M, Crazzolara R, Greil R. A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J 2006; 20: 751–756
   Google Scholar
• Barille S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995; 86: 3151–3159
   PubMed Web of Science ®Google Scholar
• Karadag A, Oyajobi B O, Apperley J F, Russell R G, Croucher P I. Human myeloma cells promote the production of interleukin-6 by primary human osteoblasts. Br J Haematol 2000; 108: 383–390
   PubMed Web of Science ®Google Scholar
• Shipman C M, Croucher P I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003; 63: 912–916
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Wezeman M J, Zangari M, Walker R, Cottler-Fox M, Gaddy D, et al. Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myeloma tous mouse model. Haematologica 2006; 91: 192–199
   PubMed Web of Science ®Google Scholar
• Ducy P, Zhang R, Geoffroy V, Ridall A L, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89: 747–754
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Kronenberg H. Minireview: transcriptional regulation in development of bone. Endocrinology 2005; 146: 1012–1017
   PubMed Web of Science ®Google Scholar
• Franceschi R T, Xiao G. Regulation of the osteoblast-specific transcription factor, Runx2: responsiveness to multiple signal transduction pathways. J Cell Biochem 2003; 88: 446–454
   PubMed Web of Science ®Google Scholar
• Geoffroy V, Kneissel M, Fournier B, Boyde A, Matthias P. High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 2002; 22: 6222–6233
   PubMed Web of Science ®Google Scholar
• Shui C, Spelsberg T C, Riggs B L, Khosla S. Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells. J Bone Miner Res 2003; 18: 213–221
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S, et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472–2483
   PubMed Web of Science ®Google Scholar
• Michigami T, Shimizu N, Williams P J, Niewolna M, Dallas S L, Mundy G R, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96: 1953–1960
   PubMed Web of Science ®Google Scholar
• Mori Y, Shimizu N, Dallas M, Niewolna M, Story B, Williams P J, et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 2004; 104: 2149–2154
   PubMed Web of Science ®Google Scholar
• van Riet I, de Greef C, del Favero H, Demanet C, Van Camp B. Production of fibronectin and adherence to fibronectin by human myeloma cell lines. Br J Haematol 1994; 87: 258–265
   PubMed Web of Science ®Google Scholar
• Ely S A, Knowles D M. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gamyelomaopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002; 160: 1293–1299
   PubMed Web of Science ®Google Scholar
• Weitzmann M N, Roggia C, Toraldo G, Weitzmann L, Pacifici R. Increased production of IL-7 uncouples bone formation from bone resorption during estrogen deficiency. J Clin Invest 2002; 110: 1643–1650
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002; 100: 4615–4621
   PubMed Web of Science ®Google Scholar
• Ehrlich L A, Chung H Y, Ghobrial I, Choi S J, Morandi F, Colla S, et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005; 106: 1407–1414
   PubMed Web of Science ®Google Scholar
• Lee J W, Chung H Y, Ehrlich L A, Jelinek D F, Callander N S, Roodman G D, et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103: 2308–2315
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, Colla S, Bonomini S, Sammarelli G, et al. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients. Blood 2006; 107: 841–842
   PubMed Web of Science ®Google Scholar
• Standal T, Abildgaard N, Fagerli U M, Stordal B, Hjertner O, Borset M, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007; 109: 3024–3030
   PubMed Web of Science ®Google Scholar
• Westendorf J J, Kahler R A, Schroeder T M. Wnt signaling in osteoblasts and bone diseases. Gene 2004; 341: 19–39
   PubMed Web of Science ®Google Scholar
• Krishnan V, Bryant H U, Macdougald O A. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202–1209
   PubMed Web of Science ®Google Scholar
• Gordon M D, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006; 281: 22429–22433
   PubMed Web of Science ®Google Scholar
• Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003; 18: 1842–1853
   PubMed Web of Science ®Google Scholar
• Niida A, Hiroko T, Kasai M, Furukawa Y, Nakamura Y, Suzuki Y, et al. DKK1, a negative regulator of Wnt signaling, is a target of the beta-catenin/TCF pathway. Oncogene 2004; 23: 8520–8526
   PubMed Web of Science ®Google Scholar
• Galli L M, Barnes T, Cheng T, Acosta L, Anglade A, Willert K, et al. Differential inhibition of Wnt-3a by Sfrp-1, Sfrp-2, and Sfrp-3. Dev Dyn 2006; 235: 681–690
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Cattley R C, Pretorius J, Asuncion F, Grisanti M, et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 2006; 39: 754–766
   PubMed Web of Science ®Google Scholar
• Morvan F, Boulukos K, Clãcment-Lacroix P, Roman-Roman S, Suc-Royer I, Vayssiere B, et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 2006; 21: 934–945
   PubMed Web of Science ®Google Scholar
• Boyden L M, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick M A, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002; 346: 1513–1521
   PubMed Web of Science ®Google Scholar
• de Boer J, Siddappa R, Gaspar C, van Apeldoorn A, Fodde R, van Blitterswijk C. Wnt signaling inhibits osteogenic differentiation of human mesenchymal stem cells. Bone 2004; 34: 818–826
   PubMed Web of Science ®Google Scholar
• Boland G M, Perkins G, Hall D J, Tuan R S. Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 2004; 93: 1210–1230
   PubMed Web of Science ®Google Scholar
• Baksh D, Boland G M, Tuan R S. Cross-talk between Wnt signaling pathways in human mesenchymal stem cells leads to functional antagonism during osteogenic differentiation. J Cell Biochem 2007; 101: 1109–1124
   PubMed Web of Science ®Google Scholar
• Baksh D, Tuan R S. Canonical and non-canonical Wnts differentially affect the development potential of primary isolate of human bone marrow mesenchymal stem cells. J Cell Physiol 2007; 212: 817–826
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007; 67: 7665–7674
   PubMed Web of Science ®Google Scholar
• Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106: 3160–3165
   PubMed Web of Science ®Google Scholar
• De Toni F, Racaud-Sultan C, Chicanne G, Mas V M, Cariven C, Mesange F, et al. A crosstalk between the Wnt and the adhesion-dependent signaling pathways governs the chemosensitivity of acute myeloid leukemia. Oncogene 2006; 25: 3113–3122
   PubMed Web of Science ®Google Scholar
• Gunn W G, Conley A, Deininger L, Olson S D, Prockop D J, Gregory C A. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2006; 24: 986–991
   PubMed Web of Science ®Google Scholar
• Lee A Y, He B, You L, Xu Z, Mazieres J, Reguart N, et al. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun 2004; 323: 1246–1250
   PubMed Web of Science ®Google Scholar
• Peng S, Miao C, Li J, Fan X, Cao Y, Duan E. Dickkopf-1 induced apoptosis in human placental choriocarcinoma is independent of canonical Wnt signaling. Biochem Biophys Res Commun 2006; 350: 641–647
   PubMed Web of Science ®Google Scholar
• Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy J D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106–2111
   PubMed Web of Science ®Google Scholar
• Robbiani D F, Chesi M, Bergsagel P L. Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 2004; 351: 197–198
   PubMed Web of Science ®Google Scholar
• Kropff M, Bisping G, Wenning D, Berdel W E, Kienast J. Proteasome inhibition in multiple myeloma. Eur J Cancer 2006; 42: 1623–1639
   PubMed Web of Science ®Google Scholar
• Garrett I R, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111: 1771–1782
   PubMed Web of Science ®Google Scholar
• Zhao M, Qiao M, Oyajobi B O, Mundy G R, Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 2003; 278: 27939–27944
   PubMed Web of Science ®Google Scholar
• Zangari M, Esseltine D, Lee C K, Barlogie B, Elice F, Burns M J, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131: 71–73
   PubMed Web of Science ®Google Scholar
• Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 2006; 7: 109–114
   PubMedGoogle Scholar
• Shimazaki C, Uchida R, Nakano S, Namura K, Fuchida S I, Okano A, et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 2005; 19: 1102–1103
   PubMed Web of Science ®Google Scholar
• Heider U, Kaiser M, Muller C, Jakob C, Zavrski I, Schulz C O, et al. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Eur J Haematol 2006; 77: 233–238
   PubMed Web of Science ®Google Scholar
• Terpos E, Heath D J, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodeling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688–692
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334–338
   PubMed Web of Science ®Google Scholar